Becton, Dickinson and Company (BD) has announced the FDA approval of first drug, diphenhydramine hydrochloride injection, USP, to be offered in BD Simplist line of prefilled generic injectables.
Diphenhydramine Hydrochloride Injection, USP, is an injectable antihistamine effective in adults and pediatric patients excluding infants and neonates.
BD executive vice president and chief operating officer William Kozy said, "We have made a significant investment in R&D and manufacturing capabilities to build a state-of-the-art manufacturing facility that combines drug formulation with our manufacturing expertise."
BD's wholly-owned subsidiary BD Rx will manufacture and commercialize the Simplist prefilled injectables designed to improve patient care and safety by reducing the injection sequence by 12 steps.
BD Rx president Mark Sebree said, "With the new BD Simplist ready-to-administer, prefilled injectables, BD is aiming to redefine injectable drug administration practice. BD envisions safe patient care and efficient clinical applications and believes this is the future of injectables."
Image: BD Simplist prefilled injectables are designed to reduce the potential risk of medication error. Photo: prnewswire/Becton, Dickinson and Company.
